本报记者 昌校宇 截至7月31日,公募基金市场已涌现12只(仅统计主代码)年内净值增长率超过100%的“翻倍基”。同时,这些业绩亮眼的产品多数聚焦创新药、医药生物、医疗保健等主题,其优异表现与港股创新药板块的持续走强密切相关。 港股创新药板块 走势强劲 港股创新药板块的强劲表现,成为推动“翻倍基”业绩的核心动力。具体来看,上述12只公募基金中,汇添富香港优势精选A以143.24%的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.